The Analytical Core has assembled a group of pioneers in the field of metabolomics who provide the most comprehensive metabolomics capabilities that exist today. The Analytical Core provides provides quantitative and semi-quantitative analyses for approximately 1,000 identified metabolites in blood plasma, urine, cerebrospinal fluid, tissue, and cell cultures by combining over 15 analytical platforms in seven research institutions under one virtual roof. Using this technology, metabolic pathways that vary in response to pharmacotheraputics will be mapped and pathway effects in complex diseases will be profiled and analyzed. During this process, thousands more compounds are detected but require structural annotation prior to pathway mapping. Extending spectral libraries and algorithms to accelerate structural annotations is part of the overall aims of the Analytical Core.
The Analytical Core provides quantitative data for probably the largest number of identified metabolites ever reported. No single analytical platform or research group could comprehensively measure all of the compounds relevant to human biochemistry. However, we have achieved this goal by combining multiple analytical platforms of seven leading laboratories in a collaborative effort to extend the breadth and depth of detection and quantification of biochemical compounds. This group brings together fifteen diverse analytical platforms in liquid and gas chromatography, mass spectrometry, electrochemical array, NMR and stable isotope based techniques. These techniques cover multiple functional signaling and processing aspects of the metabolome, including energetics, primary metabolites, neurotransmitters, lipids, markers of oxidative damage, gut function and many others. These comprehensive data are essential to the network in order to:
1. map pathways implicated in disease and in response to therapy;
2. inform pharmacogenomics researchers of candidate genes that might be mechanistically implicated in the variability of the response to treatment;
3. enable the integration of pharmacometabolomic data with pharmacogenomic data towards a systems pharmacology approach to predicting individual response to therapy. Additionally this core will advance the field of metabolomics through (a) standardizing and integrating existing analytical processes; (b) adopting and developing emerging metabolomics technologies; (c) developing a national repository for metabolomics data together with the database core.
|Oliver Fiehn||Thomas Hankemeier||Wayne Matson||Xianlin Han|
|Dan Raftery||David Wishart||David Millington||William Wikoff|